Prognostic potential of serum mesencephalic astrocyte-derived neurotrophic factor in acute intracerebral hemorrhage: a prospective observational study

Abstract Objective Mesencephalic astrocyte-derived neurotrophic factor (MANF) expressions are dramatically up-regulated in injured brain tissues, thereby conferring neurological protective effects. We intended to determine significance of serum MANF as a prognostic biomarker of intracerebral hemorrh...

Full description

Bibliographic Details
Main Authors: Cheng-Liang Zhang, Ling-Li Fang, Chuan-Liu Wang, Ping Li, Ming Yang, Jian-Wei Xu
Format: Article
Language:English
Published: BMC 2023-06-01
Series:BMC Neurology
Subjects:
Online Access:https://doi.org/10.1186/s12883-023-03254-y
_version_ 1827933350685310976
author Cheng-Liang Zhang
Ling-Li Fang
Chuan-Liu Wang
Ping Li
Ming Yang
Jian-Wei Xu
author_facet Cheng-Liang Zhang
Ling-Li Fang
Chuan-Liu Wang
Ping Li
Ming Yang
Jian-Wei Xu
author_sort Cheng-Liang Zhang
collection DOAJ
description Abstract Objective Mesencephalic astrocyte-derived neurotrophic factor (MANF) expressions are dramatically up-regulated in injured brain tissues, thereby conferring neurological protective effects. We intended to determine significance of serum MANF as a prognostic biomarker of intracerebral hemorrhage (ICH). Methods In this prospective, observational study done from February 2018 to July 2021, 124 patients with new-onset primary supratentorial ICH were consecutively enrolled. Also, a group of 124 healthy individuals constituted controls. Their serum MANF levels were detected using the Enzyme-Linked Immunosorbent Assay. National Institutes of Health Stroke Scale (NIHSS) and hematoma volume were designated as the two severity indicators. Early neurologic deterioration (END) was referred to as an increase of 4 or greater points in NIHSS scores or death at post-stroke 24 h. Post-stroke 90-day modified Rankin scale (mRS) scores of 3–6 was considered as a poor prognosis. Serum MANF levels were analyzed using multivariate analysis with respect to its association with stroke severity and prognosis. Results Patients, in comparison to controls, displayed markedly elevated serum MANF levels (median, 24.7 versus 2.7 ng/ml; P < 0.001), and serum MANF levels were independently correlated with NIHSS scores (beta, 3.912; 95% confidence interval (CI), 1.623-6.200; VIF = 2.394; t = 3.385; P = 0.002), hematoma volumes (beta, 1.688; 95% CI, 0.764–2.612; VIF = 2.661; t = 3.617; P = 0.001) and mRS scores (beta, 0.018; 95% CI, 0.013–0.023; VIF = 1.984; t = 2.047; P = 0.043). Serum MANF levels significantly predicted END and poor 90-day prognosis with areas under receiver operating characteristic curve at 0.752 and 0.787 respectively. END and prognostic predictive abilities were similar between serum MANF levels and NIHSS scores plus hematoma volumes (all P > 0.05). Combination of serum MANF levels with NIHSS scores and hematoma volumes had significantly higher prognostic capability than each of them (both P < 0.05). Serum MANF levels above 52.5 ng/ml and 62.0 ng/ml distinguished development of END and poor prognosis respectively with median-high sensitivity and specificity values. Using multivariate analysis, serum MANF levels > 52.5 ng/ml predicted END with odds ratio (OR) value of 2.713 (95% CI, 1.004–7.330; P = 0.042) and > 62.0 ng/ml predicted a poor prognosis with OR value of 3.848 (95% CI, 1.193–12.417; P = 0.024). Using restricted cubic spline, there was a linear correlation between serum MANF levels and poor prognosis or END risk (both P > 0.05). Nomograms were well established to predict END and a poor 90-day prognosis. Under calibration curve, such combination models were comparatively stable (using Hosmer & Lemeshow test, both P > 0.05). Conclusion Increased serum MANF levels after ICH, in independent correlation with disease severity, independently distinguished risks of END and 90-day poor prognosis. Therefore, serum MANF may be a potential prognostic biomarker of ICH.
first_indexed 2024-03-13T07:23:32Z
format Article
id doaj.art-aed593fd4af74701b247229ff1696a05
institution Directory Open Access Journal
issn 1471-2377
language English
last_indexed 2024-03-13T07:23:32Z
publishDate 2023-06-01
publisher BMC
record_format Article
series BMC Neurology
spelling doaj.art-aed593fd4af74701b247229ff1696a052023-06-04T11:31:57ZengBMCBMC Neurology1471-23772023-06-0123111510.1186/s12883-023-03254-yPrognostic potential of serum mesencephalic astrocyte-derived neurotrophic factor in acute intracerebral hemorrhage: a prospective observational studyCheng-Liang Zhang0Ling-Li Fang1Chuan-Liu Wang2Ping Li3Ming Yang4Jian-Wei Xu5Department of Neurology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s HospitalDepartment of Clinical Pharmacy, The Second People’s Hospital of Yuhang DistrictDepartment of Neurology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s HospitalDepartment of Respiratory and Critical Care Medicine, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s HospitalDepartment of Neurology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s HospitalDepartment of Clinic, The Quzhou Hospital of TCM, Quzhou TCM Hospital at the Junction of Four Provinces Affiliated to Zhejiang Chinese Medical UniversityAbstract Objective Mesencephalic astrocyte-derived neurotrophic factor (MANF) expressions are dramatically up-regulated in injured brain tissues, thereby conferring neurological protective effects. We intended to determine significance of serum MANF as a prognostic biomarker of intracerebral hemorrhage (ICH). Methods In this prospective, observational study done from February 2018 to July 2021, 124 patients with new-onset primary supratentorial ICH were consecutively enrolled. Also, a group of 124 healthy individuals constituted controls. Their serum MANF levels were detected using the Enzyme-Linked Immunosorbent Assay. National Institutes of Health Stroke Scale (NIHSS) and hematoma volume were designated as the two severity indicators. Early neurologic deterioration (END) was referred to as an increase of 4 or greater points in NIHSS scores or death at post-stroke 24 h. Post-stroke 90-day modified Rankin scale (mRS) scores of 3–6 was considered as a poor prognosis. Serum MANF levels were analyzed using multivariate analysis with respect to its association with stroke severity and prognosis. Results Patients, in comparison to controls, displayed markedly elevated serum MANF levels (median, 24.7 versus 2.7 ng/ml; P < 0.001), and serum MANF levels were independently correlated with NIHSS scores (beta, 3.912; 95% confidence interval (CI), 1.623-6.200; VIF = 2.394; t = 3.385; P = 0.002), hematoma volumes (beta, 1.688; 95% CI, 0.764–2.612; VIF = 2.661; t = 3.617; P = 0.001) and mRS scores (beta, 0.018; 95% CI, 0.013–0.023; VIF = 1.984; t = 2.047; P = 0.043). Serum MANF levels significantly predicted END and poor 90-day prognosis with areas under receiver operating characteristic curve at 0.752 and 0.787 respectively. END and prognostic predictive abilities were similar between serum MANF levels and NIHSS scores plus hematoma volumes (all P > 0.05). Combination of serum MANF levels with NIHSS scores and hematoma volumes had significantly higher prognostic capability than each of them (both P < 0.05). Serum MANF levels above 52.5 ng/ml and 62.0 ng/ml distinguished development of END and poor prognosis respectively with median-high sensitivity and specificity values. Using multivariate analysis, serum MANF levels > 52.5 ng/ml predicted END with odds ratio (OR) value of 2.713 (95% CI, 1.004–7.330; P = 0.042) and > 62.0 ng/ml predicted a poor prognosis with OR value of 3.848 (95% CI, 1.193–12.417; P = 0.024). Using restricted cubic spline, there was a linear correlation between serum MANF levels and poor prognosis or END risk (both P > 0.05). Nomograms were well established to predict END and a poor 90-day prognosis. Under calibration curve, such combination models were comparatively stable (using Hosmer & Lemeshow test, both P > 0.05). Conclusion Increased serum MANF levels after ICH, in independent correlation with disease severity, independently distinguished risks of END and 90-day poor prognosis. Therefore, serum MANF may be a potential prognostic biomarker of ICH.https://doi.org/10.1186/s12883-023-03254-yMesencephalic astrocyte-derived neurotrophic factorIntracerebral hemorrhageEarly neurologic deteriorationPrognosisSeverity
spellingShingle Cheng-Liang Zhang
Ling-Li Fang
Chuan-Liu Wang
Ping Li
Ming Yang
Jian-Wei Xu
Prognostic potential of serum mesencephalic astrocyte-derived neurotrophic factor in acute intracerebral hemorrhage: a prospective observational study
BMC Neurology
Mesencephalic astrocyte-derived neurotrophic factor
Intracerebral hemorrhage
Early neurologic deterioration
Prognosis
Severity
title Prognostic potential of serum mesencephalic astrocyte-derived neurotrophic factor in acute intracerebral hemorrhage: a prospective observational study
title_full Prognostic potential of serum mesencephalic astrocyte-derived neurotrophic factor in acute intracerebral hemorrhage: a prospective observational study
title_fullStr Prognostic potential of serum mesencephalic astrocyte-derived neurotrophic factor in acute intracerebral hemorrhage: a prospective observational study
title_full_unstemmed Prognostic potential of serum mesencephalic astrocyte-derived neurotrophic factor in acute intracerebral hemorrhage: a prospective observational study
title_short Prognostic potential of serum mesencephalic astrocyte-derived neurotrophic factor in acute intracerebral hemorrhage: a prospective observational study
title_sort prognostic potential of serum mesencephalic astrocyte derived neurotrophic factor in acute intracerebral hemorrhage a prospective observational study
topic Mesencephalic astrocyte-derived neurotrophic factor
Intracerebral hemorrhage
Early neurologic deterioration
Prognosis
Severity
url https://doi.org/10.1186/s12883-023-03254-y
work_keys_str_mv AT chengliangzhang prognosticpotentialofserummesencephalicastrocytederivedneurotrophicfactorinacuteintracerebralhemorrhageaprospectiveobservationalstudy
AT linglifang prognosticpotentialofserummesencephalicastrocytederivedneurotrophicfactorinacuteintracerebralhemorrhageaprospectiveobservationalstudy
AT chuanliuwang prognosticpotentialofserummesencephalicastrocytederivedneurotrophicfactorinacuteintracerebralhemorrhageaprospectiveobservationalstudy
AT pingli prognosticpotentialofserummesencephalicastrocytederivedneurotrophicfactorinacuteintracerebralhemorrhageaprospectiveobservationalstudy
AT mingyang prognosticpotentialofserummesencephalicastrocytederivedneurotrophicfactorinacuteintracerebralhemorrhageaprospectiveobservationalstudy
AT jianweixu prognosticpotentialofserummesencephalicastrocytederivedneurotrophicfactorinacuteintracerebralhemorrhageaprospectiveobservationalstudy